Ladenburg Thalmann & Co. Thinks Achieve Life Sciences’ Stock is Going to Recover


Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Achieve Life Sciences (ACHV) today and set a price target of $100.00. The company’s shares closed last Friday at $10.23, close to its 52-week low of $4.51.

According to TipRanks.com, Higgins is a 1-star analyst with an average return of -1.5% and a 33.6% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Armata Pharmaceuticals.

Currently, the analyst consensus on Achieve Life Sciences is a Moderate Buy with an average price target of $60.50, representing a 361.1% upside. In a report issued on September 18, Maxim Group also assigned a Buy rating to the stock with a $21.00 price target.

See today’s analyst top recommended stocks >>

Based on Achieve Life Sciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $2.92 million. In comparison, last year the company had a GAAP net loss of $3.62 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts